We are thrilled and feel proud to announce our expanded research collaboration with Rakovina Therapeutics to provide medicinal chemistry support to rapidly synthesize novel lead drug candidates identified by their Deep Docking AI platform.
As a Canadian chemistry R&D contract research organization for more than a decade, we have established a state-of-the-art medicinal chemistry facility relevant to AI-based small molecule drug discovery.
Our CEO Dr. Anupama Patel said: "AI based drug discovery service collaboration with Rakovina marks an important milestone for our skilled & hard-working scientists. Unlike traditional drug discovery, Deep Docking AI allows us to discover novel small molecule cancer therapeutics at an unparallel speed."
We have recently expanded our Discovery R&D / Analytical service platforms along with added manufacturing capabilities across departments and functions including Drug Discovery & Medicinal Chemistry, Custom Organic Synthesis & Bio-Polymer modifications, Chemical Process Development, Analytical/Bioanalytical Testing, Discovery Biology Services and Chiral SFC Purification capabilities.
Our newly expanded research facility caters additional Discovery R&D support to our clients across North America and delivers integrated solutions with an emphasis on quality, speed, and flexibility.
Check out the full story in the link below: https://ca.finance.yahoo.com/news/rakovina-therapeutics-announces-extensions-expansions-120000284.html
Please find further information about our expertise and capabilities on our website and feel free to contact us if you would like to have further discussion.